Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Apr;132(8):1625-9.
doi: 10.1038/sj.bjp.0704051.

Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats

S M Gardiner  1 , J E March, P A Kemp, A P Davenport, T Bennett
Affiliations

Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats

S M Gardiner et al. Br J Pharmacol. 2001 Apr.

Abstract

The regional haemodynamic effects of rat or human urotensin II (U-II) 3, 30, 300 and 3000 pmol kg(-1), i.v.) were assessed in separate groups of conscious, unrestrained, male, Sprague-Dawley rats (n=8 in each). Rat and human U-II had similar effects. At a dose of 3 pmol kg(-1), neither peptide had any significant action, while at a dose of 30 pmol kg(-1), there was a transient mesenteric vasodilatation (significant only for rat U-II). At doses of 300 and 3000 pmol kg(-1), there were dose-dependent tachycardias, and mesenteric and hindquarters hyperaemic vasodilatations. Thus, in conscious rats, the predominant cardiovascular action of rat and human U-II is vasodilatation. This is in contrast to recent findings with human U-II in non-human primates, but is consistent with effects on human isolated resistance vessels.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in heart rate and mean arterial blood pressure in conscious Sprague Dawley rats following administration of human or rat U-II (n=8 in each group). Values are mean and vertical bars show s.e.mean; *P<0.05 for a change from baseline (Friedman's test).
Figure 2
Figure 2
Changes in Doppler shift (blood flow) in conscious Sprague Dawley rats following administration of human or rat U-II (n=8 in each group). Values are mean and vertical bars show s.e.mean; *P<0.05 for a change from baseline (Friedman's test).
Figure 3
Figure 3
Changes in regional vascular conductances in conscious Sprague Dawley rats following administration of human or rat U-II (n=8 in each group). Values are mean and vertical bars show s.e.mean; *P<0.05 for a change from baseline (Friedman's test).
See this image and copyright information in PMC

References

    1. AMES R.S., SARAU H.M., CHAMBERS J.K., WILLETTE R.N., AIYAR N.V., ROMANIC A.M., LOUDEN C.S., FOLEY J.J., SAUERMELCH C.F., COATNEY R.W., AO Z., DISA J., HOLMES S.D., STADEL J.M., MARTIN J.D., LIU W.-S., GLOVER G.I., WILSON S., MCNULTY D.E., ELLIS C.E., ELSHOURBAGY N.A., SHABON U., TRILL J.J., HAY D.W.P., OHLSTEIN E.H., BERGSMA D.J., DOUGLAS S.A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282–286. - PubMed
    1. BOTTRILL F.E., DOUGLAS S.A., HILEY C.R., WHITE R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol. 2000;130:1865–1870. - PMC - PubMed
    1. CONLON J.M. Singular contributions of fish neuroendocrinology to mammalian regulatory peptide research. Regul. Pept. 2000;93:3–12. - PubMed
    1. COULOUARN Y., JÉGOU S., TOSTIVINT H., VAUDRY H., LIHRMANN I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Letts. 1999;457:28–32. - PubMed
    1. COULOUARN Y., LIHRMANN I., JEGOU S., ANOUAR Y., TOSTIVINT H., BEAUVILLAIN J.C., CONLON J.M., BERN H.A., VAUDRY H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. U.S.A. 1998;95:15803–15808. - PMC - PubMed

LinkOut - more resources